

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3997443

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ROBERT MATUNAS	05/31/2016
HERMAN CHEN	06/15/2016
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	MILLENDO THERAPEUTICS, INC.
<b>Street Address:</b>	301 N. MAIN STREET
<b>Internal Address:</b>	SUITE 100
<b>City:</b>	ANN ARBOR
<b>State/Country:</b>	MICHIGAN
<b>Postal Code:</b>	48104
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	14866212
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(206)682-6031
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	206-622-4900
<b>Email:</b>	barthz@seedip.com
<b>Correspondent Name:</b>	MICHAEL P. COOPER
<b>Address Line 1:</b>	SEED IP LAW GROUP PLLC
<b>Address Line 2:</b>	701 FIFTH AVE. SUITE 5400
<b>Address Line 4:</b>	SEATTLE, WASHINGTON 98104
<b>ATTORNEY DOCKET NUMBER:</b>	120205.405
<b>NAME OF SUBMITTER:</b>	MICHAEL P. COOPER
<b>SIGNATURE:</b>	/Michael P. Cooper/
<b>DATE SIGNED:</b>	08/08/2016
<b>Total Attachments: 5</b>	
source=Assignment by Matunas and Chen to Millendo#page1.tif	
source=Assignment by Matunas and Chen to Millendo#page2.tif	
source=Assignment by Matunas and Chen to Millendo#page3.tif	

source=Assignment by Matunas and Chen to Millendo#page4.tif

source=Assignment by Matunas and Chen to Millendo#page5.tif

## ASSIGNMENT

WHEREAS, we,

Name	Mailing Address	
Robert Matunas	2130 Massachusetts Ave, Apt. 2E, Cambridge, MA 02140	and
Herman Chen	92 Joshua Trail, Madison, CT 06443	

(hereinafter referred to as ASSIGNORS), having mailing addresses as stated above and, respectively, are the joint inventors of an invention entitled "SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO," as described and claimed in the specification for which an application for United States letters patent was filed on September 25, 2015, and assigned Application No. 14/866,212; and for which an application was filed on September 25, 2015 with the U.S. Receiving Office of the PCT and assigned Application No. PCT/US2015/052338; and for which application claims the benefit of U.S. Provisional Application No. 62/086,153, filed on December 1, 2014 and U.S. Provisional Application No. 62/055,964, filed on September 26, 2014.

WHEREAS, Millendo Therapeutics, Inc. (hereinafter referred to as ASSIGNEE), a corporation of the State of Michigan having a place of business at 301 N. Main Street, Suite 100, Ann Arbor, MI 48104, is desirous of acquiring the entire right, title and interest in and to the invention and in and to any letters patent that may be granted therefor in the United States and in any and all foreign countries;

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNORS hereby sell, assign and transfer unto said ASSIGNEE, the entire right, title and interest in and to said invention, said application and any and all letters patent which may be granted for said invention in the United States of America and its territorial possessions including any extensions or adjustments in term thereof and in any and all foreign countries, and in any and all divisions, reissues and continuations thereof, including the right to file foreign applications directly in the name of ASSIGNEE and to claim priority rights deriving from said United States application to which said foreign applications are entitled by virtue of international convention, treaty or otherwise, and including the right to sue and collect damages for past and present infringement of said


letters patent; said invention, application and all letters patent on said invention to be held and enjoyed by ASSIGNEE and its successors and assigns for their use and benefit and of their successors and assigns as fully and entirely as the same would have been held and enjoyed by ASSIGNORS had this assignment, transfer and sale not been made. ASSIGNORS hereby authorize and request the Commissioner of Patents and Trademarks to issue all letters patent on said invention to ASSIGNEE. ASSIGNORS agree to execute all instruments and documents required for the making and prosecution of applications for United States and foreign letters patent on said invention, for litigation regarding said letters patent, or for the purpose of protecting title to said invention or letters patent therefor.

5/31/16 \_\_\_\_\_ (Assignor)  
Date Robert Matunas

State of Massachusetts )  
County of Middlesex ) ss.

I certify that I know or have satisfactory evidence that Robert Matunas is the person who appeared before me, and said person acknowledged that he signed this instrument and acknowledged it to be his free and voluntary act for the uses and purposes mentioned in the instrument.

Dated 5/31/2016  
Signature of \_\_\_\_\_  
Notary Public  
Printed Name \_\_\_\_\_  
My appointment expires \_\_\_\_\_



June, 15th, 2016

Date

ChungPin Herman Chen (Assignor)  
Herman Chen

State of New Jersey

County of United State

ss.


I certify that I know or have satisfactory evidence that Herman Chen is the person who appeared before me, and said person acknowledged that he signed this instrument and acknowledged it to be his free and voluntary act for the uses and purposes mentioned in the instrument.

Dated 15th day of June, 2016

Signature of  
Notary Public Lavinia Zadroga Emery

Printed Name Lavinia Zadroga Emery

My appointment expires March 29, 2021



Application No. 14/866,212

Hovione LLC hereby acknowledges direct sale, assignment, and transfer from Robert Matunas and Herman Chen, employees of Hovione LLC, to Assignee, Millendo Therapeutics, Inc.

26 July 2016  
Date


Hovione, LLC

  
(Signatory Signature)

David Sney Head of R&D Operations  
(Signatory Name, Title)

**Millendo Therapeutics, Inc.**

July 26, 2016  
Date

 (Assignee)  
(Signatory Signature)

Jeffery M. Brinza  
SVP Administration / General Counsel  
(Assignee Signatory Name, Title)